FGF21 and Hepatic steatosis: Sex differences exist in the prevalence, risk factors, fibrosis, and clinical outcomes of NAFLD [80], and our results highlight the need for preclinical testing of FGF21 actions on liver steatosis, not only in males, but also in females.